Zymeworks Inc.ZYMEReports Mon, Nov 9 · Q3 2026
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Canada · zymeworks.com
Vancouver-based biotechnology company managing licensed assets, including Ziihera (zanidatamab) royalties, while developing multifunctional antibody therapeutics; currently acquiring Theravance Biopharma.
Key ratios
FCF / Sales
-32.6%2025
2024
-146.8%2023
-158.9%
Net margin
-126.3%TTM
2025
-76.6%2024
-160.8%2023
-156.1%
ROA
-15.8%TTM
2025
-14.3%2024
-14.6%2023
-14.0%
ROE
-42.0%TTM
2025
-26.7%2024
-30.5%2023
-24.8%
Revenue growth
38.9%2025
2024
0.4%2023
-81.6%
Recent news
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
Zymeworks Completes Acquisition of Theravance Biopharma
U.S. FDA Approves Ziihera (zanidatamab-hrii) With and Without Tislelizumab Plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
Track ZYME in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer